Incyte: I Am Moving From Hold To Buy

Impact · against what's priced in

Incyte is poised for upward movement as positive Phase 3 data for Monjuvi and the Vega Therapeutics acquisition provide concrete offsets to its Jakafi concentration risk. These pipeline developments and upward EPS revisions act as catalysts for a rating upgrade to Buy.

INCY+0.60

No priced-in read yet

In context

Promising Phase 3 data for Monjuvi in first-line DLBCL and the acquisition of Vega Therapeutics' VGA039 diversify the pipeline, mitigating the risk of over-reliance on Jakafi.

Read from the article alone

• pharmaceuticals
• earnings
• biotech
• INCY
• acquisition
• hematology
• oncology
• phase 3
• pipeline

Search tags